Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-09-27-Speech-2-115-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2011-09-27"^^xsd:date2
dcterms:Is Part Of	lp_eu:Question Time (Commission)2
dcterms:Language	"lt"^^xsd:language2
lpv:document identification number	"en.20110927.5.2-115-000"2
lpv:hasSubsequent	lp_eu:2011-09-27-Speech-2-116-0002
lpv:speaker	lp:Laima Liucija Andrikienė2
lpv:spokenAs	vice-chair; DROI (2009-07-20--2012-01-18)3 substitute; Delegation to the EU-Mexico Joint Parliamentary Committee (2009-10-12--2014-06-30)3 member; EPP (2009-07-14--2014-06-30)3 member; Delegation to the Euronest Parliamentary Assembly (2009-09-16--2014-06-30)3 member; INTA (2009-07-16--2012-01-18)3 member; Delegation for relations with Belarus (2009-09-16--2014-06-30)3 substitute; AFET (2009-07-16--2012-01-18)3 substitute; Delegation to the Euro-Latin American Parliamentary Assembly (2009-10-12--2014-06-30)3 unknown; Tėvynės sąjunga - Lietuvos krikščionys demokratai (2009-07-14--2014-06-30)3
lpv:translated text	"My question is to Commissioner De Gucht. I would like to raise an issue that has caused significant controversy in this House, namely that of ACAA, an agreement on conformity assessment and acceptance of industrial products between the EU and Israel. This agreement has already been kept on hold in this House for more than a year, even though it is purely technical in nature and concerns mutually accepted standards that will facilitate trade in pharmaceutical products. We have seen the swift acceptance of trade agreements with some third countries that are not always the most democratic or respectful of human rights. At the same time, Parliament – or at least some political groups in this House – have been effectively boycotting our relations with Israel. I would like to ask what political consequences such behaviour in one of the institutions – namely the European Parliament – will have on EU-Israel relations and the EU’s influence in the wider region? Secondly, is the Commission monitoring and assessing the damage to European pharmaceutical companies, and the additional costs European consumers of pharmaceutical products are experiencing, owing to the deliberations on this agreement in the European Parliament? My supplementary question will be that I would appreciate the comments of Commissioner Füle on this issue."@en1
lpv:unclassifiedMetadata	"Laima Liucija Andrikienė (PPE )."1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph